UCB sells speciality generics subsidiary
Wednesday, November 26, 2014 - 11:50
in Biology & Nature
Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology
Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology
